Cargando…
Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308065/ https://www.ncbi.nlm.nih.gov/pubmed/34302519 http://dx.doi.org/10.1007/s00277-021-04613-w |
| _version_ | 1783728192569212928 |
|---|---|
| author | Caocci, Giovanni Mulas, Olga Mantovani, Daniela Costa, Alessandro Galizia, Andrea Barabino, Luca Greco, Marianna Murru, Roberta La Nasa, Giorgio |
| author_facet | Caocci, Giovanni Mulas, Olga Mantovani, Daniela Costa, Alessandro Galizia, Andrea Barabino, Luca Greco, Marianna Murru, Roberta La Nasa, Giorgio |
| author_sort | Caocci, Giovanni |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8308065 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83080652021-07-26 Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis Caocci, Giovanni Mulas, Olga Mantovani, Daniela Costa, Alessandro Galizia, Andrea Barabino, Luca Greco, Marianna Murru, Roberta La Nasa, Giorgio Ann Hematol Letter to the Editor Springer Berlin Heidelberg 2021-07-24 2022 /pmc/articles/PMC8308065/ /pubmed/34302519 http://dx.doi.org/10.1007/s00277-021-04613-w Text en © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to the Editor Caocci, Giovanni Mulas, Olga Mantovani, Daniela Costa, Alessandro Galizia, Andrea Barabino, Luca Greco, Marianna Murru, Roberta La Nasa, Giorgio Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis |
| title | Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis |
| title_full | Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis |
| title_fullStr | Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis |
| title_full_unstemmed | Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis |
| title_short | Ruxolitinib does not impair humoral immune response to COVID-19 vaccination with BNT162b2 mRNA COVID-19 vaccine in patients with myelofibrosis |
| title_sort | ruxolitinib does not impair humoral immune response to covid-19 vaccination with bnt162b2 mrna covid-19 vaccine in patients with myelofibrosis |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308065/ https://www.ncbi.nlm.nih.gov/pubmed/34302519 http://dx.doi.org/10.1007/s00277-021-04613-w |
| work_keys_str_mv | AT caoccigiovanni ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT mulasolga ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT mantovanidaniela ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT costaalessandro ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT galiziaandrea ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT barabinoluca ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT grecomarianna ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT murruroberta ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis AT lanasagiorgio ruxolitinibdoesnotimpairhumoralimmuneresponsetocovid19vaccinationwithbnt162b2mrnacovid19vaccineinpatientswithmyelofibrosis |